Cite
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study
MLA
Isabella Visuri, et al. “Long-Term Outcomes of Vedolizumab in Inflammatory Bowel Disease: The Swedish Prospective Multicentre SVEAH Extension Study.” Therapeutic Advances in Gastroenterology, vol. 16, May 2023. EBSCOhost, https://doi.org/10.1177/17562848231174953.
APA
Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, Daniel Bergemalm, Henrik Hjortswang, & Jonas Halfvarson. (2023). Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study. Therapeutic Advances in Gastroenterology, 16. https://doi.org/10.1177/17562848231174953
Chicago
Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlén, Olof Grip, Charlotte Söderman, et al. 2023. “Long-Term Outcomes of Vedolizumab in Inflammatory Bowel Disease: The Swedish Prospective Multicentre SVEAH Extension Study.” Therapeutic Advances in Gastroenterology 16 (May). doi:10.1177/17562848231174953.